LLLiudmila N. Lyubchenko

Liudmila N. Lyubchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liudmila N. Lyubchenko has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inherited pathogenic variants in the PALB2 gene

    by A. I. Senderovich, L. N. Lyubchenko, Yu. L. Podberezina, S. V. Zhuravlev

    The PALB2 gene encodes a key protein involved in the most accurate mechanism of DNA double-strand break repair – homologous recombination. PALB2 acts as a link between the BRCA1 and BRCA2 proteins, ensuring the formation of a functional BRCA-complex and stimulating strand invasion by the RAD51 protein. Germline pathogenic variants in the PALB2 gene are a predisposition factor for hereditary cancer with moderate-to-high penetrance. Mutations significantly increase the risk of developing breast cancer (BC), being the third most common risk gene after BRCA1 and BRCA2, with a cumulative risk of up to 52.8 % by age 80. Furthermore, PALB2 mutations are associated with an elevated risk of ovarian, pancreatic, and prostate cancers. Biallelic mutations cause Fanconi anemia. The special clinical significance of PALB2 mutations lies in their therapeutic predictive role. The presence of germline pathogenic variants in PALB2 is a defining marker of tumor sensitivity to PARP inhibitors, such as olaparib, talazoparib, and rucaparib, which is confirmed by high objective response rates in clinical trials for BC, prostate, and pancreatic cancers. Thus, comprehensive genetic testing that includes PALB2 is becoming a necessary element of modern oncological practice for gene-specific risk assessment, personalization of prophylactic strategies, and optimization of treatment tactics through the use of targeted therapy.

  • Open Access

    Innovative genomic technologies for non-invasive cancer screening

    by L. N. Lyubchenko, K. M. Chernavina, I. A. Kaprin, R. I. Moshurov, V. S. Trifanov, V. S. Borobova, S. P. Kovalenko, QiFei(亓飞), TangLu(唐露), E. P. Zharova, et al.

    Cancer is a leading cause of mortality worldwide and the focus of priority programs and strategies for scientific and technological development in public health and health promotion. Modern screening technologies are aimed at early cancer diagnosis to improve treatment outcomes; however most of them are characterized by invasiveness and low patient compliance. Therefore, non-invasive cancer diagnosis is a promising field in molecular biology and oncology. Advances in molecular genetics and bioinformatics have enabled the identification of a wide range of diagnostic, prognostic, and predictive biomarkers, which can be analyzed not only in tumor tissue samples but also in peripheral blood. the purpose of the study was to analyze and summarize current scientific and practical data in the field of non-invasive cancer screening using molecular biological analysis, development of innovative test systems and diagnostic kits, as well as issues of legal regulation and integration into medical and social insurance programs. Material and Methods . The study was based on Russian and international scientific databases, including the National Library of Medicine using the PubMed electronic resource, Elibrary, and Google scholar search results. Open internet resources were also searched using the keywords: cancer; malignant neoplasm; tumor; diagnostic; non-invasive; early; blood; Blood-based tests; test system; screening; pancancer; multi-cancer; sequencing; PCR; marker; DNA; cfDNA; multi-cancer early detection; MCED. The analytical review included clinical trial reports, meta-analyses, systematic reviews, and cohort randomized trials for the period 2008–2025. Results. There is a steady trend worldwide towards the widespread adoption of universal, non-invasive methods for early cancer diagnosis. Retrospective and prospective multicenter studies and meta-analyses conducted over the past 15 years have demonstrated advances in interdisciplinary multimodal analysis of diverse patient data (clinical, genomic, transcriptomic, epigenomic, etc.), emphasizing the cost-effectiveness of these methods. Conclusion . Currently, large-scale population-based studies considering race and ethnicity are vital for validating methodological approaches and evaluating the effectiveness of non-invasive cancer screening methods, especially in diverse nations like Russia.

  • Open Access

    Prospects for molecular profiling in bladder cancer stratification and treatment. A review

    by Liudmila N. Lyubchenko, Karina M. Сhernavina, Koryun A. Ghazaryan, Ivan N. Zaborskiy, Oleg B. Karyakin, Любченко Людмила Николаевна, Казарян Корюн Арташесович

    Modern trends in oncological care are based on the principles of precision medicine, which necessitates the identification of prognostic and predictive molecular genetic markers. The results of genomic profiling of bladder cancer (BC) represent a wide range of genes involved in carcinogenesis, but the functional significance and clinical potential of most of them have not been sufficiently studied. The aim of this study was to summarize modern scientific and practical data on the trends in precision medicine in the field of oncourology in BC. The materials for the study were domestic and foreign scientific databases, in particular the National Library of Medicine (http://www.ncbi.nlm.nih.gov/) using the electronic resource PubMed (https://pubmed.ncbi.nlm.nih.gov/), eLIBRARY.RU (https://www.elibrary.ru/) and Google Scholar (https://scholar.google.ru/schhp?hl=ru), when searching by keywords: BC, urothelial carcinoma, NGS, molecular profiling, genes, FGFR3, TERT, PIK3CA, TP53, mutations, expression. An analytical review concerning clinical, pathomorphological and molecular genetic data on the problems of diagnosis and treatment of BC included reports on preclinical experimental and clinical studies, meta-analyses, systematic reviews, cohort randomized studies for the period 2002–2025. A number of studies have demonstrated the association of molecular genetic changes in genes encoding receptor and intracellular kinases (FGFR2/3, PIK3CA etc.) with early stages of BC carcinogenesis, provided that the multifactorial prognostic significance is variable, taking into account the availability of modern molecular-targeted drugs. In particular, a pan-FGFR inhibitor, erdafitinib, which has demonstrated its effectiveness, is currently approved for the treatment of common forms of BC. Taking into account the pathogenetic mechanisms, an important further prospect for the use of receptor and intracellular kinase inhibitors in BC is the development and introduction into clinical practice of highly selective systemic and locally delivered forms with the possibility of their use in clinically heterogeneous groups of patients, including those with early stages of the disease. In turn, alterations in genes responsible for DNA repair (TP53, etc.) are associated with an aggressive course of the disease and a corresponding less favorable prognosis. In this direction, the key point of application of personalized therapy is the development and use of agents capable of modulating the activity of proteins of the reparation system at various stages of carcinogenesis. Thus, the mutational and functional status of genes involved in key oncogenic and reparation pathways in BC plays an important role in the context of developing a prognostic model, and also serves as a predictive target for therapeutic intervention.

  • Open Access

    DPYD-associated toxicity in gastric cancer therapy: Clinical case

    by M. F. Kilmyashkina, I. V. Kolobaev, Yu. B. Karagodina, V. M. Khomyakov, L. N. Lyubchenko

    Given the high prevalence and mortality from gastric cancer in the global population, interest in the treatment of this disease is growing. The standard treatment for locally advanced gastric cancer is a combined method that includes radical surgery with perioperative polychemotherapy. For gastric cancer with distant metastases and/or a peritoneal carcinomatosis index of more than 7, as well as for the locally advanced stage, polychemotherapy based on fluoropyrimidines (FP) (5-fluorouracil, capecitabine) is used, which are characterized by the frequent development of toxic reactions. Analysis of foreign literature data with presented clinical cases of FP toxicity demonstrated that characteristic adverse events when using FP are diarrhea, nausea/vomiting, mucositis, myelosuppression, neurotoxicity and palmar-plantar syndrome. Approximately 20–30% of patients receiving FP experience severe toxicity, which can lead to death in 1% of cases, with the main cause being a deficiency of the enzyme dihydropyrimidine dihydrogenase, Due to the lack of recommendations for testing mutations and polymorphisms in the DPYD gene for gastric cancer in the Russian Federation, information on the treatment of toxic post-chemotherapy phenomena in individual clinical cases is relevant. Of particular interest is the clinical observation of a forty-three-year-old patient with morphologically verified gastric adenocarcinoma, a peritoneal carcinomatosis index of 7 and the absence of other distant metastases. After three courses of chemotherapy with the inclusion of 5-fluorouracil and oxaliplatin, the patient developed severe hematological, gastrointestinal toxicity, polyneuropathy, and therefore, on a planned basis. A molecular genetic study was performed to determine the genotype of DPYD*2A/13 associated with a high risk of toxicity during chemotherapy. According to the results of the study, a germinal missense mutation NM_000110.4(DPYD): c.2194G>A (p.Val732Ile) was detected in the DPYD gene. The presented analysis of information from scientific sources and the data of our own clinical observation demonstrate the need to assess the status of the DPYD gene in patients subject to FP therapy. The issue of registering an antidote to 5-fluorouracil and capecitabine – uridine triacetate in the Russian Federation also remains open.

  • Open Access

    Immunohistochemical features of fibrillary proteins at the dermal-epidermal junction in sepsis

    by Grigory Demyashkin, David Pogasyan, Kirill Silakov, Nathalia Pyatigorskaya, Tatyana Borovaya, Irina Ignatko, Olga Morozova, Vera Rostovskaya, Dibakhan Tsomartova, Yulii Shidlovskii, et al.

    Background/Aim: Sepsis is a life-threatening condition that significantly disrupts skin function and healing, yet the underlying mechanisms remain poorly understood. This study aimed to assess the fibrous components of the epidermal-dermal junction (Integrin-b1, laminin-332 and type IV collagen) in sepsis patients to better understand the structural changes in the skin during this condition. Methods: The study included 55 patients with sepsis (Group I) and a control group (Group II) of 10 deceased patients without infectious diseases. Patients' medical records were analysed, including clinical data, disease duration, pharmacological therapy and comorbidities. Skin biopsies were processed for histological and immunohistochemical examination to assess the expression levels of laminin-332, type IV collagen and integrin-b1. Statistical analysis was performed using SPSS 12, with p-values ≤ 0.05 considered statistically significant. Results: Histological and immunohistochemical analyses revealed significant decreases in the expression of laminin-332, type IV collagen and integrin-b1 in sepsis patients (Group I) compared to the control group (Group II). These changes were more pronounced in older patients, indicating a correlation between age and the extent of disruption. The decrease in expression of these proteins suggests partial fragmentation of the basement membrane, leading to increased permeability, impaired epidermal-dermal attachment and disruption of regenerative processes. Conclusion: The observed changes in the fibrous components of the basement membrane, particularly the reduction in integrin-b1 expression, highlight the skin's active role in the pathological process of sepsis. The impaired regenerative potential of the skin exacerbates its structural defects, hindering reparative processes and contributing to the progression of systemic inflammation. Pathological skin changes in sepsis are more pronounced in older individuals, likely due to the reduced activity of adaptive and compensatory mechanisms. Future research should focus on the recovery dynamics of these proteins and the potential for molecular-genetic analysis in understanding the long-term effects of sepsis on skin regeneration.

  • CLINICAL, EPIDEMIOLOGICAL AND REPRODUCTIVE ASPECTS OF HYPOSPADIAS. A BIBLIOGRAPHICAL REVIEW

    by Moscow Russian Scientific Center For X-Ray Radiology Of The Ministry Of Healthcare Of Russia, L.N. Lyubchenko, A.D. Kaprin

    Hypospadias refers to a congenital pathology of the genitourinary system. This bibliographical review analyzes and systematizes historical, epidemiological, clinical, populational and genetic data, highlights the problem of reproductive health of adult patients. An expert evaluation of materials related to the modern classification of hypospadias for both genders, diagnosis, surgical treatment options, family planning and childbearing taken from the PubMed database of the scientific periodicals was carried out. Authors noted the increased dynamics of the disease in the population. Hereditary predisposition of hypospadias was confirmed as well as the inverse proportionality of the severity of the disease and the ability of a patient to enter the relationships and the reproductive function in the event that hypospadias is not aggravated by testicular dysfunction, reduction of the vas deferens and other factors.


  • Open Access

    Hereditary diffuse gastric cancer associated with a novel germline variant c.1596G>A in the CDH1 gene

    by A. M. Danishevich, T. S. Lisitsa, S. E. Nikolaev, I. S. Abramov, M. G. Filippova, N. I. Pospekhova, A. M. Stroganova, M. P. Nikulin, A. E. Kalinin, I. S. Stilidi, et al.

    Gastric cancer is one of the most common malignancies worldwide. Approximately 10 % of patients with gastric cancer are characterized by accumulation of gastric cancer cases in their family. The hereditary forms of gastric cancer account for 1–3 % of all gastric cancer cases. Hereditary diffuse GC syndrome is caused by germline mutations in CDH1 gene and determines a high risk of developing diffuse GC and lobular breast cancer. In this article, we present a clinical case of a 41-year-old patient with diffuse gastric cancer, who was found to be a carrier of novel germline mutation in the CDH1 gene. Next-generation sequencing (NGS) has facilitated an identification of CDH1 c.1596GA genetic variant, thus enabling an accurate clinical diagnosis hereditary diffuse gastric cancer.

  • Open Access

    Clinical, anamnestic, molecular and genetic criteria for Lynch syndrome

    by A. V. Semyanikhina, N. I. Pospekhova, M. G. Filippova, D. A. Golovina, A. O. Rasulov, L. N. Lyubchenko

    Lynch syndrome is the most common cancer-prone syndrome associated with a high risk of colorectal cancer (CRC), neoplasms of the upper gastrointestinal system, the urinary tract, the female reproductive system, brain tumours and others. The only known form of hereditary endometrial cancer is also diagnosed as part of Lynch syndrome. One or more pathogenic germline mutations in one of the mismatch repair (MMR) genes are the cause of Lynch syndrome. Mapping of MMR genes and the discovery of microsatellite instability (MSI) have given rise to the possibility of using these clue characteristics of the pathogenic process for the elaboration of a screening test for Lynch syndrome. Being highly accurate and superior to all previously developed clinical criteria and guidelines, MSI-testing along with the assessment of the expression patterns of MMR proteins by immunohistochemistry has taken the leading role in the early diagnosis of Lynch syndrome. This article focuses on a brief review about the main evolutionary stages of clinical, anamnestic, molecular and genetic criteria for Lynch syndrome together with the results of our own research on the accuracy of the Amsterdam criteria, the Bethesda guidelines and MSI-diagnostics in the determination of the indications for MMR-genotyping in colorectal cancer patients suspected for Lynch syndrome.


  • Open Access

    Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas

    by V. Е. Bugaev, M. P. Nikulin, N. I. Pospekhova, V. M. Safronova, N. V. Kokosadze, Ya. A. Bozhchenko, S. N. Nered, L. N. Lyubchenko, I. S. Stilidi

    Background. Leiomyosarcoma is one of the most common types of soft tissue sarcomas. Radical surgical resection with subsequent adjuvant chemotherapy remain the most effective treatment approach. Immunotherapy based on inhibition of PD-L1 (programmed death ligand 1) or its receptor PD1 (programmed death 1) is considered a promising treatment option. Level of PD-L1 expression in tumor cells and presence of microsatellite instability (МSI) could be considered prognostic and predictive markers of disease progression and effectiveness of immunotherapy.The study objective is to determine PD-L1 expression level and МSI status in patients with retroperitoneal leiomyosarcomas and evaluate their effect on overall and recurrence-free survival.Materials and methods. The study included 57 patients with retroperitoneal leiomyosarcomas who underwent surgical or combination treatment. Analysis of clinical and morphological characteristics was performed; results of surgical treatment were researched. Evaluation of PD-L1 expression and MSI status was performed using immunohistochemical and molecular genetic analysis.Results. PD-L1 expression and MSI status were evaluated in 41 patients of 57. In 10 (24 %) of 41 cases, positive PD-L1 expression was observed (expression level 3–50 %). In 1 (2.4 %) patient, the primary tumor and metastatic lesion had low MSI level (MSI-low, MSI-L). Median follow-up was 31 months. In patients with positive PD-L1 expression, higher Ki-67 proliferative index was observed compared to patients with PD-L1 negative tumors (58.8 and 47.8 % respectively; р = 0.02), as well as significantly lower median overall survival for grade II tumors (30 and 105 months; p = 0.043). In grade III leiomyosarcomas, a trend towards lower median overall survival in patients with PD-L1‑negative tumors (31.0 months) compared to patients with PD-L1 expression (61.2 months) (р = 0.11) was observed.Conclusion. Among patients with retroperitoneal leiomyosarcomas, positive expression of PD-L1 was observed in 24 % (10 / 41) of cases and MSI-low status was found in 2.4 % (1 / 41) of cases. In patients with grade 2 tumors, positive PD-L1 expression is associated with significantly lower overall survival. PD-L1 expression in patients with retroperitoneal leiomyosarcomas could be considered a prognostic marker and a potential therapeutic target.

  • Open Access

    Clinical and genetic aspects of differential diagnostics of hereditary non-polyposis colorectal cancer

    by A. V. Semyanikhina, A. O. Rasulov, L. N. Lyubchenko

    Lynch syndrome was synonymous with hereditary non-polyposis colorectal cancer for a long time, however, mapping of the DNA mismatch repair (MMR) genes has led to distinguish Lynch syndrome as an independent syndromic unit from a number of Lynch-like syndromes that phenotypically mimic with the most frequent hereditary variant of colon cancer but genetically representing quite a heterogeneous group. This article presents up to date clinical and genetic characteristics of Lynch syndrome and Lynch-like conditions.